En vivo
FierceBiotechChutes & Ladders—AstraZeneca adds FDA cell and gene veteranLabiotechEight oncology deals in 2026 spotlight where industry leaders are betting bigEndpoints NewsFulcrum lays off majority of staff; Seres extends runway into 2027PharmaVoiceGSK, Takeda and others notch key clinical wins in tough-to-treat diseasesFierceBiotechHow RA Capital is offering its biotechs ‘Chinese clinical expertise in a box’Endpoints NewsNovo vet Uli Stilz settles in at Flagship; Revolution Medicines welcomes commercial execBioPharma DivePharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?Lonza NewsStipple Bio taps Lonza platform to advance ADC pipeline - The Pharma LetterCellSingle-cell mapping of regulatory DNA-protein interactionsCellPlasma signals of lung tumor promotion for molecular cancer preventionCellDeep learning of functional perturbations from condensate morphologyFierceBiotechAt first public hearing for FDA’s CNPV program, industry support meets ‘deep concern’ from experts
PharmaVoice 20 ene 2026

Texas, N. Carolina, Ohio, Pennsylvania — where pharma manufacturing investments have surged

Texas, N. Carolina, Ohio, Pennsylvania — where pharma manufacturing investments have surged

Original
Contenido no disponible. Consulta la fuente original.